BASEL, Switzerland, Feb. 9 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to announce the signing of its second License Agreement with Bato Investments, a company based out of Tel-Aviv, Israel.
This Agreement provides for a minimum yearly order of 500,000 units over a period of 10 years. Both parties have agreed on an initial price of US$ 55.00 per unit, based on the price of the recently negotiated agreement with Credo-TM, a Company based out of Russia. Each agreement is estimated to bring in a gross profit of US$ 26,750,000 annually, for a period of ten years. Negotiations are still ongoing with India, Pakistan, Spain and Egypt. The terms of these agreements are projected to be within the same range as the previous ones.
With the signing of this Agreement and ongoing negotiations, Neuro-Biotech strengthens the implementation of its Licensees network throughout the world, allowing the Company to begin the next phase of its development plan: the creation of its own "Technological Showcase" in order to support the training of technicians as well as the development of new products and avoid any type of road show.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.